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Among the different techniques speciﬁc to synchrotron radiation, the combination of X-ray
absorption spectroscopy with X-ray scattering experiments is a powerful tool to charac-
terize samples with a capability to gather structural and electronic information at the
cellular level. In the present contribution, selected examples making use of such tech-
niques point out as well the information that one can have access to. Via the presentation
of the physicochemical data, this paper focuses on displaying the information that has a
signiﬁcant clinical character.
© 2015 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The possibility to obtain complementary information
such as crystalline structure, elemental composition and
chemical speciation using non-destructive techniques is a
necessary requirement in the research proposals applied to
medical investigations as metal alloys and prostheses,
elasticity and probes, and trace elements and nephrotoxi-
city. Indeed, the samples studied, coming from human
bodies' specimens, are precious, volume limited and com-
plex. They often present a heterogeneous distribution of
chemical elements. In addition the morphology and
structure of crystallites (or amorphous compounds)
constituting the samples are supposed to be pathology
dependent. The most important objective is to determine
the local environment of speciﬁc chemical elements, and
particularly metal ions in such biological compounds. Thisil.fr (S. Reguer).
ed by Elsevier Masson SAS.is however generally a difﬁcult task. The measurements
have to be done at the micrometer scale to determine both
local order and elemental distribution in the samples
studied.
The purpose of the present short review is to describe
the opportunities given to the medical community by the
use of X-ray synchrotron radiation techniques. The intent is
not to provide a comprehensive summary of all the work
described in the literature but to give to clinicians useful
information by concentrating on particular studies using
synchrotron radiation.
The examples presented in this paper were mostly
performed at the DiffAbs beamline, implemented at SOLEIL
synchrotron (France). This beamline led to numerousmajor
scientiﬁc breakthroughs inmaterials sciences, thanks to the
available almost simultaneous combination of the
following techniques: X-Ray Diffraction (XRD), X-Ray
Fluorescence (XRF) and X-ray Absorption Spectroscopies
(XAS). As an aid toward a better description of the sample,
the combination between XRD, XRF and XAS is of primaryThis is an open access article under the CC BY-NC-ND license (http://
Fig. 1. The 6 þ 2 circles diffractometer in Kappa Geometry on the DiffAbs
beamline with (1) sample positioning using micrometric motorized tables,
(2) SDD-4E detector for XRF measurements, (3) hybrid pixel area detector
XPAD for XRD measurements.
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which it is thus possible to assess the environment of trace
elements and get a precise structural description of the
calciﬁcation. In addition, the possible access to a local probe
(about a few mm) allows us to determine the distribution of
the characterized compounds on the studied materials.
After a brief description of the DiffAbs beamline, recent
results obtained on different kinds of biological entities
including pathological calciﬁcations will be presented [1,2].
Of note, the very ﬁrst set of data collected on the SOLEIL
Synchrotron was on the DiffAbs beamline and from kidney
stone samples [3,4].
2. DiffAbs beamline
At SOLEIL Synchrotron, the DiffAbs beamline is located
on a bending magnet. A permanent magnetic ﬁeld of 1.71 T
yields a critical energy of 8.6 keV and the horizontal
angular aperture is 6 mrad. The beamline provides a
monochromatic X-ray beam, tunable in the 3e23 keV en-
ergy range and can presently operate in two modes
detailed hereafter: the standard beam mode obtained with
the main optics and the microbeam mode by adding a
secondary focusing optics.
The main optical system includes a monochromator
located between two long mirrors (50 nm Rh-coated Si).
The use of these two mirrors that collimate and focus the
beam in the vertical plane results in a high rate of harmonic
rejection and an increase of the energy resolution. The
ﬁxed-exit double crystal monochromator is composed of
two independent Si(111) crystals. The ﬁrst crystal, that is
ﬂat, allows the monochromatisation of the incident beam
by setting the incident angle and thus selecting only the X-
ray energy for which the Bragg law is fulﬁlled. The second
crystal, that is mechanically bendable, restores the paral-
lelism between the incoming and outgoing beam and
provides a sagittal focusing (in the horizontal plane) of the
monochromatic beam. This main optical set-up allows us to
obtain a monochromatic beam size less than
300  300 mm2 (H  V, Full Width Half Maximum) at the
sample position, with a photon ﬂux of about
1012e1013 ph s1.
The secondary optical system consists of two trape-
zoidal shaped orthogonally placed curved mirrors (Rh
coated) under grazing incidence (in the Kirkpatrick Baez
geometry): each of them is focusing the X-ray beam in one
direction. The beam size obtained at the sample position is
about 5  5 mm2 (H  V, FWHM) with a ﬂux close to
1010 ph s1. Apart from the obtained small and intense X-
ray spot, one of the great advantages of using KB focusing
optics is their achromaticity, making them the optics of
choice for laterally resolved spectroscopic experiments, in
particular EXAFS (Extended X-Ray Absorption Fine Struc-
ture) measurements. The applications presented in the
present paper and performed at DiffAbs were mainly
realized using the microbeam set-up.
The main experimental instrument on the DiffAbs is a
6 þ 2 circle diffractometer (Fig. 1). This high mechanical
precision instrument offers an exceptional potential for all
experiments on the beamline. The diffractometer consists
of a goniometric system with 4 circles in the Kappageometry for the sample orientation and a goniometric
system with 2 circles, concentric with the ﬁrst one, for
detector positioning in the vertical and horizontal planes.
This geometry corrects and improves the mechanical per-
formance and leaves a large free volume for heavy and
bulky sample environments. In addition, a motorized table
for the sample position in the X-ray beam and amicroscope
allow us to adjust the sample on the diffractometer and
perform X-ray imaging.
Making use of the elastic scattering and the absorption
processes, several synchrotron analysis techniques based
on XRD or XAS and XRF spectroscopies are available on the
beamline (Wide Angle X-ray Scattering, Reﬂectivity,
Anomalous Scattering, Diffraction Anomalous Fine Struc-
ture…). All the measurements are performed on the
diffractometer using different and well-adapted detectors.
Moreover, all these techniques can be used in the whole
3e23 keV energy range for both standard and micro-beam
modes and with various sample environments. This origi-
nality makes it the beamline of choice to study a large va-
riety of materials as illustrated by many different topics
[5e7]. In addition the coupling of XRD, XAS and XRF
spectroscopies is available to correlate the information
under the same experimental conditions. It means the
same X-ray spot position on the sample and thus the pos-
sibility to analyze the same area of the sample under the
same physico-chemical conditions.
From XAS measurements, it is possible to determine the
local order, that is the environment of the probed atoms
(geometry, distance of neighbors, and speciation). By XRD,
long range order is accessible, allowing, for example, the
determination of the crystallized phases, the orientation,
and other characteristics of crystals. The combination with
the microbeam scale and XRF measurements allows a good
description of the structure and distribution of the different
compounds constituting the samples studied.
Thanks to these characteristics, the DiffAbs beamline is
thus well adapted for a great part of biological samples,
though no direct access to sub-cell lateral resolution, but it
gives a lateral resolution good enough for a lot of studies.
S. Reguer et al. / C. R. Chimie 19 (2016) 1424e14311426Thus, it is possible to analyse avery small amountofmaterial,
which is interesting when sampling is limited. In addition
the concentration of the chemical element measured can be
very low, about a few hundred parts per million (ppm).3. Shedding light on arthritis
As underlined by Breedveld [8], osteoarthritis, the most
known form of arthritis, is common in the elderly but also
affects younger people. In France during the early 1990s, 6
million new cases were reported each year [9,10] in line
with the fact that worldwide 25% of adults aged over 65
years suffer from pain and disability associated with this
disease. Its prevalence is expected to increase with the
concomitant prevalence of obesity and aging [11]. Osteo-
arthritis is regarded as a complex disease whose cause is
not completely understood and leads ultimately to chronic
pain, restriction of joint mobility, and disability. Charac-
terized by articular cartilage, signiﬁcant modiﬁcations are
also observed in other joint components including bone,
menisci, synovia, ligaments, capsule, and muscles [12].
Through a panel of physicochemical techniques, among
others, XAS and XRD performed on DiffAbs and using the
microbeam set-up, the calciﬁcation process which involves
several mechanisms was studied [13e17]. Samples corre-
spond to the knee joint specimen obtained during arthro-
plasty (Fig. 2).
The samples were ﬁrst analyzed through XAS at the Ca
K-edge. The XANES (X-ray Absorption Near Edge Structure)Fig. 2. Knee joint specimen obtained during arthroplasty. The specimen
included femoral condyle and tibial plateau cartilage from both the medial
and the lateral compartments. Cartilage areas were labeled as follows: (1)
medial condyle; (2) lateral condyle; (3) medial tibial plateau; (4) lateral
tibial plateau.spectra of these samples are compared to references in
Fig. 3. A pre-peak (labeled A) is attributed to the 1s to 3d
transition and the O-2p molecular orbital, an intense
resonance corresponding to the 1s to 4p transition, and
named the white line, is observed (labeled C). This struc-
ture includes a shoulder-like feature (labeled B) corre-
sponding to the 1s to 4s transition. These XANES data
support the fact that Ca2þ compounds differ between
calciﬁed and non-calciﬁed cartilage areas. In calciﬁed areas
they appear to be mainly involved in calciﬁcations. The fact
that Ca2þ cations are involved in the crucial cellular pro-
cess, and that cartilages are not vascularized, leads to the
fact that the number of free Ca2þ is drastically decreased
locally when calciﬁcations are present in the articulation.
In addition, the samples were analyzed by the combi-
nation of XRF, XRD and XAS at the Zn K-edge (Fig. 4). The
aim was to evaluate the possible Zn accumulation close to
pathological calciﬁcations. Thesemeasurements allowed us
to correlate the distribution (especially of Ca and Zn,
Fig. 4a) obtained by the XRF map with the structure of the
compounds present determined by XRD (pyrophosphate,
Fig. 4b) and XAS realized on some points of interest
(Fig. 4c). Different Zn2þ species are present in calciﬁed
cartilage. It seems that part of Zn2þ is trapped in or at the
surface of the calciﬁcation made of pyrophosphate. Thus,Fig. 3. XANES spectra at the Ca K-edge obtained on human osteoarthritic
articular cartilage compounds and compared to carbapatite (red solid line),
amorphous carbonated Ca2þ apatite (red dotted line), Ca2þ pyrophosphate
dehydrate (black solid line) and non-diffusible tissue Ca2þ (blue solid line
with circles). The (a) to (f) spectra correspond to measures on samples from
patients. On theses XANES spectra, the A to D positions correspond to
speciﬁc features explained in the text.
Fig. 4. (a) mXRF maps showing Zn and Ca distribution in human cartilage (sample MEM2) with points of interest (b) mXRD image using the XPAD3.2 detector on
the sample MEM2 compared to a reference compound (monoclinic pyrophosphate) (c) XANES spectra obtained on the points of interest (from 1 to 6, also noted
on the maps) for the sample MEM2.
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the associated biological function of Zn2þ metalloproteins.
4. Nephrolithiasis described by XANES investigations
The relationship between vitamin D, Randall's plaque
and nephrolithiasis is nowadays still debated [18]. Indeed,
Randall's plaque, which serves as a nucleus of kidney
stones, constitutes a major public health problem since a
dramatic increase in the prevalence of kidney stones
developed from a Randall's plaque is observed in western
countries [19e21]. In 2010, more than 55% of calcium ox-
alate (CaOx) kidney stones display a Randall's plaque at
their surface in young stone formers aged 20 to 30 years
instead of 16% in the 1990s [22e24].
In order to determine locally (from several 10 to 100 mm
scale) the structure of phases constituting such Randall's
plaque, the environment of Ca was investigated [25]. The
studied papillae came from two different kidneys at Nice
Hospital after nephrectomy for tumor (Fig. 5). The XAS
spectra, performed at the Ca K-edge on the DiffAbs beam-
line and using themicrobeam set-up, are presented in Fig. 6
and compared to references such as biological apatite (CA
for CarbApatite) and its precursor (ACCP for Amorphous
Carbonated Calcium Phosphate). As from the previous
example, speciﬁc features describe the spectra. While
feature A is quite the same in the biological apatite (CA) and
its precursor (ACCP), signiﬁcant variations are measured forshoulder B as well as for the double peak at the maximum
of the white line (labeled C1 and C2). Such signiﬁcant dif-
ferences allow us to describe precisely the environment of
Ca even if the sample is hydrated.
The XANES results suggest that Randall's plaque is
composed mainly of ACCP and not of CA. ACCP is evidence
of an oversaturation in calcium phosphate by an excess of
calcium and/or phosphate and/or due to a too high pH. Its
presence in increasingly young subjects raises the ques-
tion: does nutrient-enriched food specially aimed at young
children affect the physiology of the kidney? The debate is
still open.5. Osteoporosis and strontium ranelate, the local
environment of Sr2þ
Osteoporosis, characterized by an increase in bone
fragility due to low bone mass and deterioration of bone
quality, affects an estimated 75 million people in Europe,
USA and Japan corresponding to more than 8.9 million
fractures annually [26]. The public health burden of oste-
oporotic fractureswill rise in future generations, due in part
to an increase in life expectancy. Recently, strontium-drug
has been introduced as a pharmacological agent for the
treatment and prevention of osteoporosis and has shown
anti-fracture efﬁcacy in the treatment of postmenopausal
osteoporosis [27e29].
Fig. 5. studied samples: (a) Randall's plaque (white deposit) at the surface of
kidney stone (b) Randall's plaque (white deposit) at the surface of a papilla.
Fig. 6. XANES spectra at the Ca K-edge of two Randall's plaque (RP, dot lines)
is compared to reference compounds; synthetic well crystallized stoichio-
metric Ca phosphate apatite (HAP, red), crystallized biological Ca phosphate
apatite (CA, blue dots) exhibiting nm sized crystals, amorphous carbonated
calcium phosphate (ACCP, black with circles).
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localization of Sr2þ cations in human bones. For example,
Rossi et al. [30] have collected electron energy loss near
edge structures from P, C, Ca and Sr and showed physico-
chemical modiﬁcations in the bone mineral at the nano-
scale caused by the systemic administration of strontium
ranelate. In order to observe mineralization changes, Busse
et al. [31] have performed quantitative backscattered
electron imaging and energy-dispersive X-ray analyses
combined with micro-XRF. The complete study suggests
that strontium ranelate might be considered as a thera-
peutic option for patients following long-term bisphosph-
onate treatment. The proton induced X-ray emission (PIXE)
method can also be used for the determination of
elemental concentrations in femoral heads [32]. More
recently, Wohl et al. [33] have evaluated the accumulation
of strontium in bones through in vivo XRF in rats supple-
mented with strontium citrate and strontium ranelate.
Scattering techniques can be used but as underlined in a
recent publication [34], these techniques [35e38] are
sensitive to Sr content within the mineral crystals but
ignore other types of non-crystalline strontium deposits.
Several academic research studies [39e43] have evalu-
ated the modiﬁcations of the crystal size during the inser-
tion of Sr2þ cations into apatite. Bigi et al. [41] and Suganthi
et al. [43] found very different results regarding the effect of
Sr2þ on the crystallinity and the crystallite size of hy-
droxyapatite (HAP). In fact, the complete set of such studies
indicates clearly that the insertion of Sr2þ cations in apatite
is a complex process which is very sensitive to preparation
methods. Structural investigation through XAS has also
been performed [44e50].
The local environment of Sr2þ cations in biological ap-
atites (Fig. 7) present in pathological and physiological
calciﬁcations in patients without such Sr-based drugs was
assessed through XAS experiments on DiffAbs [51,52].
The different structural hypotheses (Fig. 8a) regarding
the localization of Sr2þ cations in bone which take intoFig. 7. Illustration of the typical physiological sample investigated in this
study.
Fig. 8. (a) Three different structural hypothesis regarding the adsorption at the surface of Ca phosphate apatite of Sr2þ cations or its insertion. (b) EXAFS
modulations of the absorption coefﬁcient as calculated for each structural hypothesis. (c) EXAFS modulations after the Sr K-edge for different samples.
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been presented previously [52].
- hypothesis I : Sr2þ cations, only surrounded by oxygen
atoms [49,50], are adsorbed at the surface of collagen
or apatite.- hypothesis II : Sr2þ cations are engaged in the hydrated
poorly crystalline apatite region present at the surface
of calcium phosphate nanocrystals.
- hypothesis III : Sr2þ cations are inside Ca phosphate
nanocrystals on either crystallographic site (CaI) or
(CaII).
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initio theoretical simulation of the XANES part of the ab-
sorption spectra and quantitative analyses taking into ac-
count multiple scattering processes of the EXAFS data were
combined. In fact, EXAFS analysis seems to be the more
efﬁcient way to select a structural model (Fig. 8b). Data
measured after the Sr K-edge are very similar to ones
previously measured [49e54] in which Sr2þ cations are
located inside the apatite crystal. Moreover, the complete
set of experimental data collected on 17 physiological and
pathological calciﬁcations seems to indicate that there is no
relationship between the nature of the calciﬁcation
(physiological and pathological) and the adsorption mode
of Sr2þ cations (simple adsorption or insertion).
6. Similar investigations on other beamlines
Research at the interface between physics, chemistry
and medicine has also been performed on other beamlines
implemented on other synchrotron facilities. Quite
recently, Bohic et al. [55] have described the possibilities
offered by XRF and XAS in the biomedical ﬁeld through
very interesting examples of applications performed at the
ESRF synchrotron-based microspectroscopy platform. We
would like to hereafter assess two examples in order to
show the complexity as well as the wealth of such research.
The ﬁrst example is given by Pt based drugs which are
widely used in oncology [56]. To assess the electronic state
as well as the local environment of Pt, XAS measurements
are of great help. Indeed, the analysis of the XANES edge
height provides information about the relative proportions
of Pt(II) and Pt(IV) complexes [57] and the EXAFS data
analysis gives important results on the surrounding envi-
ronment of Pt [58e62]. Among the different break-
throughs, Serimaa et al. [63] described for the ﬁrst time the
PtePt partial radial distribution function of a biologically
active Pt complex and explained the structure by using a
mixture model where the major components are mono-
and bi-nuclear Pt complexes. More recently, Beret et al. [60]
gave evidence of a slight hydration structure around the Pt
complex. A parallel, which can be established between the
chemistry of Pt drugs and that of the Pt catalyst, has been
already underlined [64].
Another example is given by physiological calciﬁcations:
the major part of the investigations based on XAS mea-
surements at the Ca K-edge is related to this physiological
calciﬁcation [50,54,65e69]. Peters et al. [69] indicated that
the size and morphology of the bone mineral particles are
independent of the nature of the bone origin and that
signiﬁcant differences in the overall composition of the
bone samples and in the carbonate content of the mineral
phase exist. Similar results were obtained by Harries et al.
[70]. Major information can be gathered also through
XANES performed at the Ca L2,3-edges as these measure-
ments are as well indicative of the local structure around Ca
and can be performed on intracellular inclusions [71e74].
7. Conclusion and perspectives
This presentation of investigations regarding patholog-
ical calciﬁcations through different examples shows theimportance of X-ray techniques using synchrotron radiation
to achieve meaningful and effective analysis for medical
applications. The few examples in the present paper show
the crucial role of speciﬁc beamlines, such as the DiffAbs
beamline at SOLEIL, where it is possible to combine different
techniques, such as XRF, XRD and XAS. Particularly, imaging
techniques are crucial and reveal a lot of information.
Indeed, thanks to the rapid acquisition obtained by coupling
the very great brightness of the synchrotron source and the
temporal performances of new detectors (such as hybrid
pixel detectors for example) it is now possible to realize
simultaneously large XRF and XRD maps to correlate
elemental and structural information. Furthermore the
recent development of the “ﬂyscan” method will strongly
increase the acquisition performances, as it aims to realize
acquisition in a continuous mode [75]. Another important
instrument evolution on the DiffAbs beamline is linked to
the current development of a new 2D hybrid pixel detector
covering a large angular domain. Such instruments will
allow us to perform rapid XRD measurements but also will
improve the possibility of diffraction-tomography and Pair
Distribution Function (PDF) analyzes.
Different technical aspects of the cited synchrotron
techniques are not totally exploited and other existing
techniques are not yet developed in this ﬁeld. For this
reason, in addition to the already interesting results ob-
tained, the scientiﬁc studies presented in this paper also
open up new ideas for next scientiﬁc development in this
ﬁeld of research. For example, numerous major break-
throughs, and innovative applications regarding medical
nanotechnology are now available [76e78], for example,
nanometre-scale metallic clusters which have interesting
natural bactericidal and fungicidal properties [79]. Further
research in this domain is typically required to focus on
theranostics, as deﬁned by the combination of therapeutic
and diagnostic agents on the very same single nanoparticle
which is emerging as a very promising therapeutic para-
digm. For such nanomaterials, opportunities to perform at
the same time a characterization of nanometer scale clus-
ters by XRD and of drug containing Pt by XAS will lead to
major scientiﬁc breakthroughs regarding the deciphering
of their interaction with tumors [79].
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